Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 59Gynecologic 51Thoracic 32Gastrointestinal 29Genitourinary 7Head & Neck 6Sarcoma 4Dermatologic 4CNS 2Plasma cell 1Other solid neoplasm 1Other 1Lymphoid 1Endocrine 1

Conditions

Multiple Myeloma 1

Interventions

Dexamethasone 293Lenalidomide 162Bortezomib 160Cyclophosphamide 121Calcium Dobesilate 118Melphalan 116fludarabine phosphate 75carfilzomib 62pomalidomide 57Whole-Body Irradiation 57Mycophenolic Acid 56Granulocyte Colony-Stimulating Factor 55Peripheral Blood Stem Cell Transplantation 54Filgrastim 54fludarabine 50daratumumab 50Tacrolimus 45Busulfan 45ixazomib 42Thalidomide 37Cyclosporine 32Stem Cell Transplantation 29dexamethasone acetate 28Antilymphocyte Serum 26dexamethasone 21-phosphate 23plerixafor 21elotuzumab 20auricularum 20belantamab mafodotin 19Prednisone 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Taxes × Plasma cell × Clear all
NCT01646762 2017-10-16

Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Relapsed or Refractory Multiple Myeloma

Mayo Clinic

Phase 2 Terminated
13 enrolled 11 charts
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡